Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Atracurium (compound)

Summary
General Info

PubChem

PubChem Compound 10034347

PubChem Compound 10034347

Name:	Atracurium
PubChem Compound ID:	10034347
Description:	A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Molecular formula:	C₅₃H₇₂N₂O₁₂⁺₂
Molecular weight:	929.145 g/mol

DrugBank

Identification

Name:	Atracurium
Name (isomeric):	DB00732
Drug Type:	small molecule
Description:	A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Category:	Neuromuscular Nondepolarizing Agents, Nicotinic Antagonists
CAS number:	64228-79-1

Pharmacology

Indication:	For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Pharmacology:	Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, ... show more » Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results. show less «
Mechanism of Action:	Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Half Life:	The elimination half-life is approximately 20 minutes.
Toxicity:	Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Tobramycin	The agent increases the effect of the muscle relaxant
Quinine	The quinine derivative increases the effect of the muscle relaxant
Azathioprine	The agent decreases the effect of the muscle relaxant
Phenytoin	Phenytoin decreases the effect of the muscle relaxant
Aminophylline	Theophylline decreases the effect of muscle relaxant

Targets

Neuronal acetylcholine receptor subunit alpha-2